Skip to main content
. 2025 Jan 7;15:1488175. doi: 10.3389/fendo.2024.1488175

Table 6.

Characterization of the preoperative PpIX-TSLT clusters.

Time Cluster 1
N=21
Cluster 2
N=15
FDR adj.
p value
Clinical variables
Age (years) T0 40.0 [34.0-52.0]; n=21 58.0 [51.5-61.0]; n=15 0.045
Sex (female) T0 19 (90.5%); n=21 10 (66.7%); n=15 0.27
Body height (cm) T0 166.0 [161.0-170.0]; n=21 171.0 [163.0-177.5]; n=15 0.46
Weight (kg) T0 122.0 [113.0-130.0]; n=21 132.0 [123.5-149.0]; n=15 0.23
Body Mass Index (kg/m²) T0 43.6 [41.3-47.1]; n=21 48.5 [44.0-50.6]; n=15 0.32
Excess weight (kg) T0 59.4 [53.6-74.0]; n=21 75.9 [62.1-79.9]; n=15 0.27
Years with obesity (years) T0 25.0 [16.5-34.0]; n=19 31.5 [22.0-40.0]; n=14 0.44
Diabetes mellitus T0 3 (14.3%) 6 (40.0%) 0.27
Arterial hypertension T0 13 (61.9%) 13 (86.7%) 0.27
Dyslipidemia T0 3 (14.3%) 4 (26.7%) 0.46
OSA T0 4 (19.0%)a 5 (33.3%)a 0.46
GERD T0 7 (33.3%)b 6 (40.0%)b 0.74
PpIX-TSLT variables
MitoPO2:baseline (mmHg) T0 74.2 [63.8-89.7]; n=21 46.6 [40.2-53.5]; n=15 <0.001
T3 63.8 [48.0-84.5]; n=17 56.2 [43.1-66.4]; n=11 0.264
T5 75.3 [62.6-96.3]; n=16 63.0 [57.2-70.7]; n=11 0.100
MitoVO2:avg (mmHg/s) T0 5.1 [4.1-5.6]; n=21 2.3 [2.1-3.3]; n=15 <0.001
T3 4.1 [3.3-5.2]; n=17 3.5 [2.7-4.4]; n=11 0.507
T5 3.0 [2.2-4.1]; n=16 2.7 [2.2-3.5]; n=11 0.512
MitoDO2:avg (mmHg/s) T0 4.5 [3.1-6.4]; n=21 2.5 [1.7-3.9]; n=15 0.010
T3 5.3 [3.0-7.2]; n=17 3.6 [3.2-5.0]; n=11 0.451
T5 4.6 [4.0-5.9]; n=16 3.2 [2.5-6.7]; n=11 0.507
Weight variables
Body weight (kg) T2 105.5 [99.0-113.8]; n=17 113.0 [106.0-126.0]; n=13 0.36
T3 92.0 [86.7-102.0]; n=20 103.0 [94.9-121.2]; n=15 0.12
T4 83.1 [79.4-95.0]; n=20 102.4 [87.1-110.0]; n=13 0.07
T5 80.6 [76.4-86.6]; n=20 98.3 [88.4-103.6]; n=14 0.028
Body Mass Index (kg/m²) T2 38.2 [34.4-42.8]; n=17 39.8 [38.2-43.1]; n=13 0.36
T3 32.5 [30.7-37.6]; n=20 37.2 [32.6-39.1]; n=15 0.15
T4 29.8 [28.8-34.1]; n=20 33.7 [31.8-36.3]; n=13 0.07
T5 28.2 [26.4-33.3]; n=20 32.8 [30.9-34.3]; n=14 0.028
Total weight loss (%) T2 14.9 [12.5-18.0]; n=17 15.0 [12.4-18.0]; n=13 0.93
T3 24.7 [21.4-28.1]; n=20 21.9 [18.8-25.6]; n=15 0.22
T4 30.4 [27.4-34.4]; n=20 26.9 [24.1-29.6]; n=13 0.07
T5 35.6 [30.9-38.7]; n=20 28.1 [22.4-30.9]; n=14 0.041
Excess weight (kg) T2 43.8 [34.2-56.1]; n=17 49.9 [43.9-60.8]; n=13 0.36
T3 29.6 [25.8-42.3]; n=20 44.6 [30.4-49.9]; n=15 0.15
T4 22.6 [18.8-33.7]; n=20 32.8 [27.0-40.7]; n=13 0.07
T5 17.2 [13.3-31.0]; n=20 32.1 [24.3-36.4]; n=14 0.028
Excess weight loss (%) T2 32.8 [26.5-39.3]; n=17 33.9 [32.0-36.8]; n=13 0.85
T3 54.7 [48.5-66.4]; n=20 48.4 [42.3-55.6]; n=15 0.15
T4 71.2 [64.4-79.9]; n=20 57.7 [54.2-63.7]; n=13 0.028
T5 84.1 [70.7-91.1]; n=20 62.2 [53.2-68.9]; n=14 0.011

All data in median [interquartile range] or absolute and relative frequencies (%). Differences in continuous variables were tested using Mann-Whitney U tests. For categorical variables, we applied Fisher’s exact tests. False-discovery rate (FDR) adjusted p values < 0.05 are printed in bold.

GERD, Gastroesophageal reflux disease; mitoPO2, mitochondrial oxygen tension; mitoVO2, mitochondrial oxygen consumption; mitoDO2, mitochondrial oxygen delivery; OSA, obstructive sleep apnea; PpIX-TSLT, Protoporphyrin IX-Triplet State Lifetime Technique; T0, preoperative; T1, day of surgery (no data acquisition); T2, 3 ± 1 months; T3, 6 ± 1 months; T4, 9 ± 1 months; T5, 12 ± 1 months after laparoscopic sleeve gastrectomy.

raw p value <0.05; p values were FDR adjusted separately for clinical, PpIX-TSLT, and weight variables.